Stryker said the Newnan, Ga.-based cranial implant maker’s assets will complement its existing craniomaxillofacial product offering.
Porex develops bio-implantable porous polyethylene products for use primarily in reconstructive surgery of the head and face, according to its website.
“The acquisition of Porex Surgical further expands on our presence in the [craniomaxillofacial] market and allows us to broaden our product offering to both patients and clinicians,” said Stryker CEO Stephen MacMillan in prepared remarks.
The terms of the deal were not released. Stryker does not expect the transaction to affect its 2010 and 2011 earnings per share, according to the company.
The Kalamazoo, Mich.-based company yesterday announced the acquisition of Boston Scientific Corp.’s neurovascular business for $1.5 billion.